At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 19, 2026 at 08:00 ET
Chemomab Therapeutics reported its full-year and Q4 2025 financial results, highlighted by a successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), alignment on a single Phase 3 trial for potential approval, and strong clinical data presentations. The company has $10.4M in cash, sufficient to fund operations into Q1 2027, while R&D expenses declined due to completion of its Phase 2 trial.
- FDA aligned with Chemomab on a single Phase 3 trial as a potential path to full approval for nebokitug in PSC, with a clinical event-driven primary endpoint.
- Phase 2 SPRING trial data published in peer-reviewed journals and presented at major liver disease conferences, including AASLD and DDW, with multiple 'posters of distinction' and a Best Oral Presentation award.
- Cash position was $10.4 million as of December 31, 2025, down from $14.3 million in 2024, but provides runway into Q1 2027.
- R&D expenses decreased to $5.8M in 2025 from $11.3M in 2024 due to completion of the Phase 2 trial.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access